GLP-1 receptor agonists first entered the market in 2005 with the approval of exenatide (Byetta) for type 2 diabetes
In order to avoid further HIF-1 degradation during whole cell lysates preparation, cells were lysed directly with NuPAGE LDS Sample Buffer (1X) (Thermo Fisher Scientific, San Jose, CA, USA) in the presence of protease and phosphatase inhibitors cocktail (Cell Signaling Technology, Danvers, MA, USA), similarly to ref
Regulatory update (August 2026): Melanotan II was not reviewed at the July 2324, 2026 PCAC hearing and has no scheduled PCAC review date as of August 2026
Combining two metabolically active agents that influence body composition and hormonal signalling introduces a range of potential safety concerns, even when each drug is used individually within its intended parameters
Hydrophobic ion pairing: altering the solubility properties of biomolecules